November
Venture Capital & Private Equity
Investment Challenges and Opportunities in Emerging Biotech Markets

Bruce Kovacs
Afecta Pharmaceuticals
Christopher Mizer
President and CEO Vivaris Capital
Daniel Gebremedhin
Partner Flare Capital Partners
George Ng
Board Director, President & COO Calidi Biotherapeutics
Igor O. Nasonkin
CEO Phythera Therapeutics
Klaus Simonsen
Vice President, Head of External Research & Innovation LundbeckOur Agenda
Private Equity, Venture Capital & Strategic Partnerships
Topic TBC
Igor O. Nasonkin,
CEO,
Phythera Therapeutics
Private Equity, Venture Capital & Strategic Partnerships
Collaborative Chemistry: The Business of Partnerships in Drug Innovation (Topic TBC)
Klaus Simonsen,
Vice President, Head of External Research & Innovation,
Lundbeck
Private Equity, Venture Capital & Strategic Partnerships
How Strategic Partnerships Revolutionize Pharma R&D
Private Equity, Venture Capital & Strategic Partnerships
Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery
Private Equity, Venture Capital & Strategic Partnerships
The Role of Venture Partnerships in Drug Discovery (Topic TBC)
Bruce Kovacs,
President/CEO,
Afecta Pharmaceuticals
Private Equity, Venture Capital & Strategic Partnerships
Aligning Capital, Capability, and Curiosity: The Future of Venture and Partnership in Drug Discovery
Private Equity & Venture Capital
Maximizing ROI in Clinical Trials: Navigating Risk, Innovation, and Opportunity
Dan Gebremedhin,
Partner,
Flare Capital Partners
Private Equity & Venture Capita
Balancing Cost-Effectiveness with Data Reliability in Decentralized Models
Private Equity & Venture Capital
Crossroads Between Life Sciences and Cryptocurrency in Investing
George Ng,
Chief Executive Officer,
Processa Pharmaceutical
Private Equity & Venture Capital
Evaluating the Role of Strategic Partnerships in Mitigating Risks and Enhancing Funding or Expertise for Clinical Trials
Christopher Mizer,
President and Chief Executive Officer,
Vivaris Capital
Private Equity & Venture Capital
De-Risking Investment in Clinical Trials: Strategies for Startups and VCs
Engage in Real Conversations That Matter
Our unique roundtable format fosters meaningful dialogue—not lectures—so you gain actionable insights from every discussion. Choose up to four roundtable sessions, each limited to 20 participants, and connect with senior-level peers in a relaxed, collaborative setting.
Further Information
Interested in attending this virtual roundtable or running your own? Drop us a message today and we will get in touch
Here To Help
Need help registering your team? Just get in touch and a member of the team will be happy to help.